Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers.

Clinical pharmacology and therapeutics - 1 Mar 1990

Veronese M E, Miners J O, Randles D, Gregov D, Birkett D J

Abstract excerpt

The present study has validated kinetically a convenient method to measure tolbutamide hydroxylation capacity in human beings by use of urinary metabolic ratios. The known in vivo and in vitro inhibitory properties of sulfaphenazole were used to convert control phase subjects to phenotypically "poor" metabolizers of tolbutamide. Six healthy subjects were given a single 500 mg oral dose of tolbutamide with and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Chromatography

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Half-Life

Share to Hydroxylation

Share to Phenotype

Share to Random Allocation

Source

Identifiers

PMID: 2311340
DOI: 10.1038/clpt.1990.46

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers.PMID 2311340Read ↗

Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans.Semantic proximity Read ↗

Cytochrome P450 2C9 phenotyping using low-dose tolbutamide.Semantic proximity Read ↗

Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach.Semantic proximity Read ↗

Evaluation of cytochrome P4502C9 metabolic activity with tolbutamide in CYP2C91 heterozygotes.Semantic proximity Read ↗

Reaction Phenotyping of Low-Turnover Compounds in Long-Term Hepatocyte Cultures Through Persistent Selective Inhibition of Cytochromes P450.Semantic proximity Read ↗

Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans.Semantic proximity Read ↗

Use of chlorzoxazone as an in vivo probe of cytochrome P450 2E1: choice of dose and phenotypic trait measure.Semantic proximity Read ↗

Unexpected Effect of Rifampin on the Pharmacokinetics of Linezolid: In Silico and In Vitro Approaches to Explain Its MechanismSemantic proximity Read ↗

Salivary analysis for determination of dextromethorphan metabolic phenotype.Semantic proximity Read ↗

Phenotypic analysis of human CYP2C9 polymorphisms using fluorine-substituted tolbutamide.Semantic proximity Read ↗

Re-evaluation of the metabolism of carbocisteine in a British white population.Semantic proximity Read ↗

Cytochrome P450 2C9 mediated metabolism in people with and without cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.